Edition:
India

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

14.28USD
19 Jul 2018
Change (% chg)

$0.17 (+1.20%)
Prev Close
$14.11
Open
$14.11
Day's High
$14.35
Day's Low
$13.96
Volume
198,081
Avg. Vol
279,567
52-wk High
$17.98
52-wk Low
$11.47

Latest Key Developments (Source: Significant Developments)

Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The U.S.
Tuesday, 24 Apr 2018 

April 24 (Reuters) - GlaxoSmithKline ::FDA APPROVED EXPANDED INDICATION FOR TRELEGY ELLIPTA IN THE U.S. FOR TREATMENT OF PATIENTS WITH COPD.  Full Article

GSK and Innoviva announce positive data from COPD study
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Glaxosmithkline Plc :GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.GSK - ‍POSITIVE DATA FROM A STUDY COMPARING A ONCE-DAILY LAMA AND LABA FIXED-DOSE COMBINATION, ANORO ELLIPTA AND STIOLTO RESPIMAT FOR COPD​.GSK - ‍ENDPOINT WAS MET, AND UMEC/VI DEMONSTRATED SUPERIORITY TO TIO/OLO, WITH A DIFFERENCE IN TREATMENT EFFECT OF 52ML ON TROUGH FEV1 AT WEEK EIGHT ​.GLAXOSMITHKLINE PLC - ‍MOST FREQUENTLY-REPORTED ADVERSE EVENTS WERE UPPER RESPIRATORY TRACT INFECTIONS, COUGH AND DIARRHOEA​.GLAXOSMITHKLINE PLC - ‍BOTH TREATMENTS DEMONSTRATED A COMPARABLE TOLERABILITY AND SAFETY PROFILE​.GLAXOSMITHKLINE PLC - ‍OVERALL INCIDENCE OF ON-TREATMENT ADVERSE EVENTS OF 25% IN UMEC/VI GROUP AND 31% IN TIO/OLO GROUP​.  Full Article

Innoviva reports Q3 adj earnings $0.31/shr
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Innoviva Inc :Innoviva reports third quarter 2017 financial results and provides business updates.Q3 adjusted earnings per share $0.31.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Innoviva Inc - ‍plans to repurchase up to $80 million of common stock, pursuant to an accelerated share repurchase (ASR) plan​.Innoviva Inc - qtrly ‍total revenue $48.6 million versus $33.3 million.Q3 revenue view $57.2 million -- Thomson Reuters I/B/E/S.  Full Article

GSK presents positive results from phase III FULFIL study
Tuesday, 6 Sep 2016 

GlaxoSmithKline Plc : Gsk presents positive results from phase iii fulfil study of closed triple combination therapy ff/umec/vi versus symbicort® turbohaler® in copd at ers international congress . Study which reported headline results in june 2016, met its two co-primary endpoints .Plans are on schedule for regulatory submissions of closed triple combination therapy for copd in us and europe by end of 2016.  Full Article

BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35

* Q1 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S